Distinguished in Hepatitis

Graham S. Cooke

London, ENG, GB 
Distinguished in Hepatitis
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Graham Cooke practices in London, United Kingdom. Mr. Cooke is rated as a Distinguished expert by MediFind in the treatment of Hepatitis. His top areas of expertise are Hepatitis C, Hepatitis, Severe Acute Respiratory Syndrome (SARS), and HIV/AIDS.

His clinical research consists of co-authoring 240 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 80 articles and participated in 2 clinical trials in the study of Hepatitis.

Gender
Male

Locations

London, ENG SW72AZ, United Kingdom
Other Locations
Oxford, ENG, United Kingdom
United Kingdom
Hammersmith, ENG, United Kingdom
Kensington, ENG SW72AZ, United Kingdom
Guy's And St. Thomas' NHS Foundation Trust, Kingston Upon Hull, ENG, United Kingdom
Glasgow, SCT G128QQ, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An Open Label, Multicentre, International Pilot Study of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir With or Without Ribavirin or Glecaprevir/Pibrentasvir for People With Recently Acquired Hepatitis C Virus Infection With or Without HIV Co-infection.
An Open Label, Multicentre, International Pilot Study of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir With or Without Ribavirin or Glecaprevir/Pibrentasvir for People With Recently Acquired Hepatitis C Virus Infection With or Without HIV Co-infection.
Enrollment Status: Completed
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drugs: Paritaprevir+Ritonavir+Ombitasvir, Dasabuvir, Ribavirin, Glecaprevir+Pibrentasvir
Study Phase: Phase 3
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Enrollment Status: Completed
Publish Date: December 11, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

240 Total Publications

HCV response-guided therapy: is shorter always better? - Authors' reply.
HCV response-guided therapy: is shorter always better? - Authors' reply.
Journal: Lancet (London, England)
Published: September 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cooke's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile